Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy DOI Creative Commons
Yufei Lu,

Zhao Fu

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: April 28, 2025

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B and plasma malignancies, numerous promising targets against solid tumours are being explored. Despite their initial therapeutic success in hematological cancers, relapse occurs a significant fraction patients, highlighting need for further innovations advancing CAR therapy. Tumour heterogeneity acquired tumour resistance leading to escape (antigen loss/downregulation) have emerged as crucial factor contributing immune resistance, particularly case with only limited achieved date. In this review, we discuss mechanisms strategies that under development overcome multiple mechanisms, thereby reducing outgrowth variants. Specifically, emphasize importance designing clinical translational enhance crosstalk host cells, eliciting endogenous antitumour responses through antigen/epitope spreading, which offers genuine solution limitations targeting monospecific therapies.

Language: Английский

Epigenetic enhancement of adoptive T cell immunotherapy DOI
Zhenyu Dai, Melody Smith

Cancer Cell, Journal Year: 2025, Volume and Issue: 43(3), P. 340 - 342

Published: March 1, 2025

Language: Английский

Citations

0
Epigenetic Landscapes Drive CAR-T Cell Kinetics and Fate Decisions: Bridging Persistence and Resistance DOI
Kecheng Wang,

Kaixin Ou,

Yu Zeng

et al.

Critical Reviews in Oncology/Hematology, Journal Year: 2025, Volume and Issue: unknown, P. 104729 - 104729

Published: April 1, 2025

Language: Английский

Citations

0
Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy DOI Creative Commons
Yufei Lu,

Zhao Fu

Molecular Cancer, Journal Year: 2025, Volume and Issue: 24(1)

Published: April 28, 2025

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of B and plasma malignancies, numerous promising targets against solid tumours are being explored. Despite their initial therapeutic success in hematological cancers, relapse occurs a significant fraction patients, highlighting need for further innovations advancing CAR therapy. Tumour heterogeneity acquired tumour resistance leading to escape (antigen loss/downregulation) have emerged as crucial factor contributing immune resistance, particularly case with only limited achieved date. In this review, we discuss mechanisms strategies that under development overcome multiple mechanisms, thereby reducing outgrowth variants. Specifically, emphasize importance designing clinical translational enhance crosstalk host cells, eliciting endogenous antitumour responses through antigen/epitope spreading, which offers genuine solution limitations targeting monospecific therapies.

Language: Английский

Citations

0